ETFA KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.
Alpha-ETF, EMA, ETFA_HUMAN, Electron transfer flavoprotein alpha polypeptide, Electron transfer flavoprotein alpha subunit, Electron transfer flavoprotein subunit alpha mitochondrial, Electron transferring flavoprotein alpha polypeptide, GA2, Glutaric aciduria II
ETFA KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
ETFA or Electron-Transfer-Flavoprotein alpha subunit is an essential part of the mitochondrial respiratory chain. This protein which has a molecular mass of approximately 34 kDa functions in the transfer of electrons from acyl-CoA dehydrogenases to the main respiratory chain for energy production. ETFA is commonly expressed in tissues with high-energy demands such as the liver heart and skeletal muscle. The protein forms a heterodimeric complex with its counterpart ETFB providing a critical function in electron transfer during fatty acid oxidation.
ETFA operates as an important part of the electron transfer process within the mitochondria. It acts as one-half of the heterodimeric electron-transfer flavoprotein complex teaming with ETFB. This complex facilitates electron transfer from a range of acyl-CoA dehydrogenases to ETF dehydrogenase which then continues the process of electron transfer to coenzyme Q in the respiratory chain. This action is key to the breakdown of fats enabling energy extraction and processing.
ETFA has important roles in fatty acid beta-oxidation and amino acid catabolism. It engages in these pathways by transferring electrons as mentioned interfacing with other proteins like ETF dehydrogenase. This positioning within the mitochondrial matrix enables ETFA to assist in converting fat and protein substrates into energy which the cell can use. Its molecular interactions highlight its integral position in maintaining energy homeostasis.
Problems with ETFA lead to glutaric acidemia type 2 a metabolic disorder that impairs the body's ability to oxidize fatty acids and some amino acids. Deficiencies in ETFA function disrupt the electron transport to the respiratory chain causing an accumulation of intermediary metabolites. These disruptions can relate to or involve other mitochondrial components and proteins like ETFB or ETFDH. Correct diagnosis and understanding of ETFA’s role in such conditions are instrumental for targeted therapeutic approaches.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Anti-ETFA antibody [2B11AE8] ab110316 was shown to specifically react with ETFA in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line Human ETFA knockout HEK-293T cell line ab266513 (knockout cell lysate ab257943) was used. Wild-type and ETFA knockout samples were subjected to SDS-PAGE. Anti-ETFA antibody [2B11AE8] ab110316 and Anti-beta Tubulin [EP1331Y] - Microtubule Marker (Anti-beta Tubulin antibody [EP1331Y] - Microtubule Marker ab52901) were incubated overnight at 4oC at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-ETFA antibody [2B11AE8] (Anti-ETFA antibody [2B11AE8] ab110316) at 1/1000 dilution
Lane 1: Wild-type HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 40 µg
Lane 2: ETFA knockout HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 40 µg
Lane 2: Western blot - Human ETFA knockout HEK-293T cell line (Human ETFA knockout HEK-293T cell line ab266513)
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/10000 dilution
Predicted band size: 35 kDa, 81 kDa
Observed band size: 35 kDa
Homozygous: Insertion of the selection cassette in exon 1
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com